Leptomeningeal Metastases of Breast Cancer: Toward New Therapies
Abstract
Objective: Diverse preclinical models of leptomeningeal metastases (LM) will be established reflecting patient heterogeneity and methods of spread, and incorporating an intact immune system. I hypothesize that molecular analysis of the model systems and patient LM will identify potential mechanistic pathways that can be experimentally validated and tested for preclinical drug efficacy. I hypothesize that LM are infiltrated by immune cells and may be treatable by IT immune checkpoint therapy. Impact: Development of a panel of LM model systems and sharing to interested researchers will jumpstart this field of research. Potential mechanistic pathways underlying LM will be identified and mechanistically tested. The role of IT therapy for these pathways will be tested preclinically. The immune contribution to LM progression will be characterized and tested with anti-PD-1/PDL1, delivered by multiple routes. Any successful preclinical experiments can lead to a LM prevention or treatment clinical trial to be conducted at the NCI, and potentially Walter Reed.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1126394
Entities
People
- Patricia Steeg
Organizations
- Geneva Foundation